{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:39:11Z","timestamp":1791819551194,"version":"4.3.4"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007051","name":"Uppsala University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007051","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sensitive and specific blood biomarkers for early detection of colorectal (CRC), lung (LuCa) and ovarian (OvCa) cancers are highly warranted. The current blood tests often need to be complemented with other clinical methods to achieve adequate diagnostic performance. Recent progress in the molecular profiling of plasma from cancer patients holds potential for improved non-invasive screening. Here, we aimed to identify composite proteomic and metabolomic plasma biomarkers for early cancer detection with performances that exceed those of existing FDA-approved blood and stool-based diagnostic tests for CRC, LuCa and OvCa.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In a case-control study using samples from the U-CAN and EpiHealth biobanks, we measured plasma levels of 165 proteins and 244 metabolites in 818 patients with CRC, LuCa and OvCa at diagnosis, 119 patients with non-malignant conditions of the corresponding organs, and 1,129 healthy individuals. We performed an exhaustive search over all cut-off values of the ROC for all combinations of up to 4 proteins and metabolites, implementing measures to minimize the impact of cross-cohort comparisons. Ultimately, we benchmarked candidate biomarkers performance to FDA approved blood tests in clinical use for detection of cancer. External validation was performed using publicly available datasets.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We found biomarkers composed of 2\u20134 proteins separating cases of each tumor type from healthy controls with ROC AUC, respectively for CRC: CEACAM5, FLT1, IL19, Ferritin (AUC 0.89), LuCa: FNDC5, MDK, PLAUR, CEACAM5 (AUC 0.91) and OvCa: MUC16\/CA125, PLG (AUC 0.97). The diagnostic performance of these biomarkers was comparable to, and in some instances surpassed, the performance of established tests, such as Epi proColon (AUC 0.82) and Cologuard (AUC 0.93). Metabolites were informative for tumor stage discrimination, especially in LuCa and OvCa. External validation in the CancerSeek dataset showed strong agreement in biomarker performance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The composite protein biomarkers identified in this study represent a novel opportunity for detection, staging and differential diagnosis of common tumor types. Metabolites are more relevant for tumor staging than early detection. A limited number of well-performing analytes enables cost-effective implementation in clinical diagnostics and merits further evaluation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12943-026-02654-1","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T01:15:20Z","timestamp":1775524520000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Composite proteomic and metabolomic plasma biomarkers for detection of colorectal, lung and ovarian cancers"],"prefix":"10.1186","volume":"25","author":[{"given":"Jim \u00c5kerr\u00e9n","family":"\u00d6gren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joakim","family":"Ekstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natallia","family":"Rameika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Torell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chatarina","family":"Larsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivaylo","family":"Stoimenov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Micke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Gyllensten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats","family":"Hellstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bengt","family":"Glimelius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"St\u00e5lberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Sj\u00f6blom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,7]]},"reference":[{"key":"2654_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"2654_CR2","doi-asserted-by":"publisher","first-page":"l408","DOI":"10.1136\/bmj.l408","volume":"364","author":"N Hawkes","year":"2019","unstructured":"Hawkes N. Cancer survival data emphasise importance of early diagnosis. BMJ. 2019;364:l408.","journal-title":"BMJ"},{"key":"2654_CR3","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12\u201349.","journal-title":"CA Cancer J Clin"},{"key":"2654_CR4","first-page":"233","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2023. CA Cancer J Clin. 2023;73:233\u201354.","journal-title":"CA Cancer J Clin"},{"key":"2654_CR5","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/ijc.32089","volume":"145","author":"M Vicentini","year":"2019","unstructured":"Vicentini M, Zorzi M, Bovo E, Mancuso P, Zappa M, Manneschi G, Mangone L, Giorgi Rossi P. Colorectal Cancer Screening Iswg. Impact of screening programme using the faecal immunochemical test on stage of colorectal cancer: Results from the IMPATTO study. Int J Cancer. 2019;145:110\u201321.","journal-title":"Int J Cancer"},{"key":"2654_CR6","doi-asserted-by":"publisher","first-page":"e032773","DOI":"10.1136\/bmjopen-2019-032773","volume":"9","author":"HC Jodal","year":"2019","unstructured":"Jodal HC, Helsingen LM, Anderson JC, Lytvyn L, Vandvik PO, Emilsson L. Colorectal cancer screening with faecal testing, sigmoidoscopy or colonoscopy: a systematic review and network meta-analysis. BMJ Open. 2019;9:e032773.","journal-title":"BMJ Open"},{"key":"2654_CR7","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa1911793","volume":"382","author":"HJ de Koning","year":"2020","unstructured":"de Koning HJ, van der Aalst CM, de Jong PA, Scholten ET, Nackaerts K, Heuvelmans MA, Lammers JJ, Weenink C, Yousaf-Khan U, Horeweg N, et al. Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. N Engl J Med. 2020;382:503\u201313.","journal-title":"N Engl J Med"},{"key":"2654_CR8","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1056\/NEJMoa1102873","volume":"365","author":"T Research","year":"2011","unstructured":"National Lung Screening Trial, Research T, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM, Sicks JD. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365:395\u2013409.","journal-title":"N Engl J Med"},{"key":"2654_CR9","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1016\/S0140-6736(21)00731-5","volume":"397","author":"U Menon","year":"2021","unstructured":"Menon U, Gentry-Maharaj A, Burnell M, Singh N, Ryan A, Karpinskyj C, Carlino G, Taylor J, Massingham SK, Raikou M, et al. Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2021;397:2182\u201393.","journal-title":"Lancet"},{"key":"2654_CR10","first-page":"622","volume":"73","author":"GD Coronado","year":"2024","unstructured":"Coronado GD, Jenkins CL, Shuster E, Johnson C, Amy D, Cook J, Sahnow S, Zepp JM, Mummadi R. Blood-based colorectal cancer screening in an integrated health system: a randomised trial of patient adherence. Gut. 2024;73:622\u20138.","journal-title":"Gut"},{"key":"2654_CR11","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1126\/science.aar3247","volume":"359","author":"JD Cohen","year":"2018","unstructured":"Cohen JD, Li L, Wang Y, Thoburn C, Afsari B, Danilova L, Douville C, Javed AA, Wong F, Mattox A, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science. 2018;359:926\u201330.","journal-title":"Science"},{"key":"2654_CR12","doi-asserted-by":"publisher","first-page":"4221","DOI":"10.1158\/1078-0432.CCR-21-0417","volume":"27","author":"X Chen","year":"2021","unstructured":"Chen X, Dong Z, Hubbell E, Kurtzman KN, Oxnard GR, Venn O, Melton C, Clarke CA, Shaknovich R, Ma T, et al. Prognostic significance of blood-based multi-cancer detection in plasma cell-free DNA. Clin Cancer Res. 2021;27:4221\u20139.","journal-title":"Clin Cancer Res"},{"key":"2654_CR13","doi-asserted-by":"publisher","first-page":"3475","DOI":"10.1038\/s41467-020-17316-z","volume":"11","author":"X Chen","year":"2020","unstructured":"Chen X, Gole J, Gore A, He Q, Lu M, Min J, Yuan Z, Yang X, Jiang Y, Zhang T, et al. Non-invasive early detection of cancer four years before conventional diagnosis using a blood test. Nat Commun. 2020;11:3475.","journal-title":"Nat Commun"},{"key":"2654_CR14","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/j.annonc.2021.05.806","volume":"32","author":"EA Klein","year":"2021","unstructured":"Klein EA, Richards D, Cohn A, Tummala M, Lapham R, Cosgrove D, Chung G, Clement J, Gao J, Hunkapiller N, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021;32:1167\u201377.","journal-title":"Ann Oncol"},{"key":"2654_CR15","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.annonc.2020.02.011","volume":"31","author":"MC Liu","year":"2020","unstructured":"Liu MC, Oxnard GR, Klein EA, Swanton C, Seiden MV, Consortium C. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann Oncol. 2020;31:745\u201359.","journal-title":"Ann Oncol"},{"key":"2654_CR16","doi-asserted-by":"publisher","unstructured":"Neal RD, Johnson P, Clarke CA, Hamilton SA, Zhang N, Kumar H, et al. Cell-free DNA-based multi-cancer early detection test in an asymptomatic screening population (NHS-Galleri): design of a pragmatic, prospective randomised controlled trial. Cancers (Basel). 2022;14(19):4818. https:\/\/doi.org\/10.3390\/cancers14194818.","DOI":"10.3390\/cancers14194818"},{"key":"2654_CR17","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1001\/jama.2025.7515","volume":"334","author":"A Shaukat","year":"2025","unstructured":"Shaukat A, Burke CA, Chan AT, Grady WM, Gupta S, Katona BW, Ladabaum U, Liang PS, Liu JJ, Putcha G, et al. Clinical validation of a circulating tumor DNA-based blood test to screen for colorectal cancer. JAMA. 2025;334:56\u201363.","journal-title":"JAMA"},{"key":"2654_CR18","doi-asserted-by":"publisher","first-page":"e0295685","DOI":"10.1371\/journal.pone.0295685","volume":"18","author":"JL Schneider","year":"2023","unstructured":"Schneider JL, Johnson CA, Jenkins C, Mummadi R, Coronado GD. I was screaming hallelujah: Patient and provider perceptions of blood-based testing for colorectal cancer screening. PLoS ONE. 2023;18:e0295685.","journal-title":"PLoS ONE"},{"key":"2654_CR19","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1097\/CEJ.0000000000000352","volume":"27","author":"EL Symonds","year":"2018","unstructured":"Symonds EL, Cock C, Meng R, Cole SR, Fraser RJL, Young GP. Uptake of a colorectal cancer screening blood test in people with elevated risk for cancer who cannot or will not complete a faecal occult blood test. Eur J Cancer Prev. 2018;27:425\u201332.","journal-title":"Eur J Cancer Prev"},{"key":"2654_CR20","doi-asserted-by":"publisher","first-page":"e000355","DOI":"10.1136\/bmjgast-2019-000355","volume":"7","author":"R Hariharan","year":"2020","unstructured":"Hariharan R, Jenkins M. Utility of the methylated SEPT9 test for the early detection of colorectal cancer: a systematic review and meta-analysis of diagnostic test accuracy. BMJ Open Gastroenterol. 2020;7:e000355.","journal-title":"BMJ Open Gastroenterol"},{"key":"2654_CR21","doi-asserted-by":"publisher","first-page":"3032","DOI":"10.1038\/s41598-017-03321-8","volume":"7","author":"L Song","year":"2017","unstructured":"Song L, Jia J, Peng X, Xiao W, Li Y. The performance of the SEPT9 gene methylation assay and a comparison with other CRC screening tests: A meta-analysis. Sci Rep. 2017;7:3032.","journal-title":"Sci Rep"},{"key":"2654_CR22","doi-asserted-by":"publisher","first-page":"319","DOI":"10.7326\/M18-2390","volume":"170","author":"TF Imperiale","year":"2019","unstructured":"Imperiale TF, Gruber RN, Stump TE, Emmett TW, Monahan PO. Performance characteristics of fecal immunochemical tests for colorectal cancer and advanced adenomatous polyps: a systematic review and meta-analysis. Ann Intern Med. 2019;170:319\u201329.","journal-title":"Ann Intern Med"},{"key":"2654_CR23","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1053\/j.gastro.2019.08.023","volume":"157","author":"K Selby","year":"2019","unstructured":"Selby K, Levine EH, Doan C, Gies A, Brenner H, Quesenberry C, Lee JK, Corley DA. Effect of sex, age, and positivity threshold on fecal immunochemical test accuracy: a systematic review and meta-analysis. Gastroenterology. 2019;157:1494\u2013505.","journal-title":"Gastroenterology"},{"key":"2654_CR24","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.14309\/ajg.0000000000000445","volume":"114","author":"LJW Bosch","year":"2019","unstructured":"Bosch LJW, Melotte V, Mongera S, Daenen KLJ, Coupe VMH, van Turenhout ST, Stoop EM, de Wijkerslooth TR, Mulder CJJ, Rausch C, et al. Multitarget Stool DNA Test Performance in an Average-Risk Colorectal Cancer Screening Population. Am J Gastroenterol. 2019;114:1909\u201318.","journal-title":"Am J Gastroenterol"},{"key":"2654_CR25","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1056\/NEJMoa1311194","volume":"370","author":"TF Imperiale","year":"2014","unstructured":"Imperiale TF, Ransohoff DF, Itzkowitz SH, Levin TR, Lavin P, Lidgard GP, Ahlquist DA, Berger BM. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014;370:1287\u201397.","journal-title":"N Engl J Med"},{"key":"2654_CR26","doi-asserted-by":"publisher","first-page":"109215","DOI":"10.1016\/j.cmpb.2025.109215","volume":"276","author":"J Ekstrom","year":"2026","unstructured":"Ekstrom J, Stoimenov I, Akerren Ogren J, Sjoblom T. Biomarker discovery study design consistent with the receiver-operator characteristic. Comput Methods Programs Biomed. 2026;276:109215.","journal-title":"Comput Methods Programs Biomed"},{"key":"2654_CR27","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1080\/0284186X.2017.1337926","volume":"57","author":"B Glimelius","year":"2018","unstructured":"Glimelius B, Melin B, Enblad G, Alafuzoff I, Beskow A, Ahlstrom H, Bill-Axelson A, Birgisson H, Bjor O, Edqvist PH, et al. U-CAN: a prospective longitudinal collection of biomaterials and clinical information from adult cancer patients in Sweden. Acta Oncol. 2018;57:187\u201394.","journal-title":"Acta Oncol"},{"key":"2654_CR28","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s10654-013-9787-x","volume":"28","author":"L Lind","year":"2013","unstructured":"Lind L, Elmstahl S, Bergman E, Englund M, Lindberg E, Michaelsson K, Nilsson PM, Sundstrom J. EpiHealth: a large population-based cohort study for investigation of gene-lifestyle interactions in the pathogenesis of common diseases. Eur J Epidemiol. 2013;28:189\u201397.","journal-title":"Eur J Epidemiol"},{"key":"2654_CR29","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.3390\/cancers15061788","volume":"15","author":"J Ekstrom","year":"2023","unstructured":"Ekstrom J, Akerren Ogren J, Sjoblom T. Exact Probability Distribution for the ROC Area under Curve. Cancers (Basel). 2023;15:1788.","journal-title":"Cancers (Basel)"},{"key":"2654_CR30","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/BF01229068","volume":"29","author":"T Kishida","year":"1994","unstructured":"Kishida T, Sato J, Fujimori S, Minami S, Yamakado S, Tamagawa Y, Taguchi F, Yoshida Y, Kobayashi M. Clinical significance of serum iron and ferritin in patients with colorectal cancer. J Gastroenterol. 1994;29:19\u201323.","journal-title":"J Gastroenterol"},{"key":"2654_CR31","doi-asserted-by":"publisher","first-page":"6111","DOI":"10.1158\/1078-0432.CCR-10-0119","volume":"16","author":"N Wild","year":"2010","unstructured":"Wild N, Andres H, Rollinger W, Krause F, Dilba P, Tacke M, Karl J. A combination of serum markers for the early detection of colorectal cancer. Clin Cancer Res. 2010;16:6111\u201321.","journal-title":"Clin Cancer Res"},{"key":"2654_CR32","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1186\/1471-2407-12-393","volume":"12","author":"S Bunger","year":"2012","unstructured":"Bunger S, Haug U, Kelly M, Posorski N, Klempt-Giessing K, Cartwright A, Fitzgerald SP, Toner V, McAleer D, Gemoll T, et al. A novel multiplex-protein array for serum diagnostics of colon cancer: a case-control study. BMC Cancer. 2012;12:393.","journal-title":"BMC Cancer"},{"key":"2654_CR33","first-page":"4935","volume":"35","author":"IJ Christensen","year":"2015","unstructured":"Christensen IJ, Brunner N, Dowell B, Davis G, Nielsen HJ, Newstead G, King D. Plasma TIMP-1 and CEA as Markers for Detection of Primary Colorectal Cancer: A Prospective Validation Study Including Symptomatic and Non-symptomatic Individuals. Anticancer Res. 2015;35:4935\u201341.","journal-title":"Anticancer Res"},{"key":"2654_CR34","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12014-017-9163-z","volume":"14","author":"LJ Croner","year":"2017","unstructured":"Croner LJ, Dillon R, Kao A, Kairs SN, Benz R, Christensen IJ, Nielsen HJ, Blume JE, Wilcox B. Discovery and validation of a colorectal cancer classifier in a new blood test with improved performance for high-risk subjects. Clin Proteom. 2017;14:28.","journal-title":"Clin Proteom"},{"key":"2654_CR35","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1177\/1533034616674323","volume":"16","author":"Q Li","year":"2017","unstructured":"Li Q, Wang K, Su C, Fang J. Serum Trefoil Factor 3 as a Protein Biomarker for the Diagnosis of Colorectal Cancer. Technol Cancer Res Treat. 2017;16:440\u20135.","journal-title":"Technol Cancer Res Treat"},{"key":"2654_CR36","doi-asserted-by":"publisher","first-page":"742","DOI":"10.3892\/ol.2020.11633","volume":"20","author":"H Luo","year":"2020","unstructured":"Luo H, Shen K, Li B, Li R, Wang Z, Xie Z. Clinical significance and diagnostic value of serum NSE, CEA, CA19-9, CA125 and CA242 levels in colorectal cancer. Oncol Lett. 2020;20:742\u201350.","journal-title":"Oncol Lett"},{"key":"2654_CR37","doi-asserted-by":"publisher","first-page":"273","DOI":"10.2147\/CEG.S251633","volume":"13","author":"L Rasmussen","year":"2020","unstructured":"Rasmussen L, Nielsen HJ, Christensen IJ. Early Detection and Recurrence of Colorectal Adenomas by Combination of Eight Cancer-Associated Biomarkers in Plasma. Clin Exp Gastroenterol. 2020;13:273\u201384.","journal-title":"Clin Exp Gastroenterol"},{"key":"2654_CR38","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/1479-5876-11-253","volume":"11","author":"SB Thorsen","year":"2013","unstructured":"Thorsen SB, Lundberg M, Villablanca A, Christensen SL, Belling KC, Nielsen BS, Knowles M, Gee N, Nielsen HJ, Brunner N, et al. Detection of serological biomarkers by proximity extension assay for detection of colorectal neoplasias in symptomatic individuals. J Transl Med. 2013;11:253.","journal-title":"J Transl Med"},{"key":"2654_CR39","doi-asserted-by":"publisher","first-page":"92254","DOI":"10.18632\/oncotarget.21173","volume":"8","author":"W Fei","year":"2017","unstructured":"Fei W, Chen L, Chen J, Shi Q, Zhang L, Liu S, Li L, Zheng L, Hu X. RBP4 and THBS2 are serum biomarkers for diagnosis of colorectal cancer. Oncotarget. 2017;8:92254\u201364.","journal-title":"Oncotarget"},{"key":"2654_CR40","doi-asserted-by":"publisher","first-page":"3046","DOI":"10.3892\/ol.2020.11846","volume":"20","author":"J Sun","year":"2020","unstructured":"Sun J, Chen X, Wang Y. Comparison of the diagnostic value of CEA combined with OPN or DKK1 in non-small cell lung cancer. Oncol Lett. 2020;20:3046\u201352.","journal-title":"Oncol Lett"},{"key":"2654_CR41","doi-asserted-by":"publisher","unstructured":"Wu H, Wang Q, Liu Q, Zhang Q, Huang Q, Yu Z. The serum tumor markers in combination for clinical diagnosis of lung cancer. Clin Lab. 2020;66(3). https:\/\/doi.org\/10.7754\/Clin.Lab.2019.190533.","DOI":"10.7754\/Clin.Lab.2019.190533"},{"key":"2654_CR42","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/j.rmed.2009.05.019","volume":"103","author":"GH Shang","year":"2009","unstructured":"Shang GH, Jia CQ, Tian H, Xiao W, Li Y, Wang AH, Dong L, Lin DJ. Serum high mobility group box protein 1 as a clinical marker for non-small cell lung cancer. Respir Med. 2009;103:1949\u201353.","journal-title":"Respir Med"},{"key":"2654_CR43","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.2147\/CMAR.S155693","volume":"10","author":"F Chen","year":"2018","unstructured":"Chen F, Shen J, Wang J, Cai P, Huang Y. Clinical analysis of four serum tumor markers in 458 patients with ovarian tumors: diagnostic value of the combined use of HE4, CA125, CA19-9, and CEA in ovarian tumors. Cancer Manag Res. 2018;10:1313\u20138.","journal-title":"Cancer Manag Res"},{"key":"2654_CR44","doi-asserted-by":"publisher","first-page":"e1003295","DOI":"10.1371\/journal.pmed.1003295","volume":"17","author":"G Funston","year":"2020","unstructured":"Funston G, Hamilton W, Abel G, Crosbie EJ, Rous B, Walter FM. The diagnostic performance of CA125 for the detection of ovarian and non-ovarian cancer in primary care: A population-based cohort study. PLoS Med. 2020;17:e1003295.","journal-title":"PLoS Med"},{"key":"2654_CR45","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.ygyno.2018.03.050","volume":"149","author":"C Han","year":"2018","unstructured":"Han C, Bellone S, Siegel ER, Altwerger G, Menderes G, Bonazzoli E, Egawa-Takata T, Pettinella F, Bianchi A, Riccio F, et al. A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma. Gynecol Oncol. 2018;149:585\u201391.","journal-title":"Gynecol Oncol"},{"key":"2654_CR46","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1111\/jog.14427","volume":"46","author":"AA Lertkhachonsuk","year":"2020","unstructured":"Lertkhachonsuk AA, Buranawongtrakoon S, Lekskul N, Rermluk N, Wee-Stekly WW, Charakorn C. Serum CA19-9, CA-125 and CEA as tumor markers for mucinous ovarian tumors. J Obstet Gynaecol Res. 2020;46:2287\u201391.","journal-title":"J Obstet Gynaecol Res"},{"key":"2654_CR47","first-page":"604","volume":"24","author":"Y Li","year":"2020","unstructured":"Li Y, Wang ZC, Luo L, Mu CY, Xu J, Feng Q, Li SB, Gu B, Ma P, Lan T. The clinical value of the combined detection of sEGFR, CA125 and HE4 for epithelial ovarian cancer diagnosis. Eur Rev Med Pharmacol Sci. 2020;24:604\u201310.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2654_CR48","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s12938-018-0581-6","volume":"17","author":"HJ Song","year":"2018","unstructured":"Song HJ, Yang ES, Kim JD, Park CY, Kyung MS, Kim YS. Best serum biomarker combination for ovarian cancer classification. Biomed Eng Online. 2018;17:152.","journal-title":"Biomed Eng Online"},{"key":"2654_CR49","doi-asserted-by":"publisher","first-page":"e29533","DOI":"10.1371\/journal.pone.0029533","volume":"6","author":"P Yip","year":"2011","unstructured":"Yip P, Chen TH, Seshaiah P, Stephen LL, Michael-Ballard KL, Mapes JP, Mansfield BC, Bertenshaw GP. Comprehensive serum profiling for the discovery of epithelial ovarian cancer biomarkers. PLoS ONE. 2011;6:e29533.","journal-title":"PLoS ONE"},{"key":"2654_CR50","doi-asserted-by":"publisher","first-page":"258","DOI":"10.14712\/fb2016062060258","volume":"62","author":"JH Zivny","year":"2016","unstructured":"Zivny JH, Leahomschi S, Klener P Jr., Zivny J, Haluzik M, Cibula D. Comparison of Plasma Osteopontin Levels between Patients with Borderline Ovarian Tumours and Serous Ovarian Carcinoma. Folia Biol (Praha). 2016;62:258\u201362.","journal-title":"Folia Biol (Praha)"},{"key":"2654_CR51","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1002\/ijc.33351","volume":"148","author":"MM He","year":"2021","unstructured":"He MM, Fang Z, Hang D, Wang F, Polychronidis G, Wang L, Lo CH, Wang K, Zhong R, Knudsen MD, et al. Circulating liver function markers and colorectal cancer risk: A prospective cohort study in the UK Biobank. Int J Cancer. 2021;148:1867\u201378.","journal-title":"Int J Cancer"},{"key":"2654_CR52","doi-asserted-by":"publisher","first-page":"e0165615","DOI":"10.1371\/journal.pone.0165615","volume":"11","author":"PD Chandler","year":"2016","unstructured":"Chandler PD, Akinkuolie AO, Tobias DK, Lawler PR, Li C, Moorthy MV, Wang L, Duprez DA, Jacobs DR, Glynn RJ, et al. Association of N-Linked Glycoprotein Acetyls and Colorectal Cancer Incidence and Mortality. PLoS ONE. 2016;11:e0165615.","journal-title":"PLoS ONE"},{"key":"2654_CR53","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.jpba.2014.08.020","volume":"100","author":"S Deja","year":"2014","unstructured":"Deja S, Porebska I, Kowal A, Zabek A, Barg W, Pawelczyk K, Stanimirova I, Daszykowski M, Korzeniewska A, Jankowska R, Mlynarz P. Metabolomics provide new insights on lung cancer staging and discrimination from chronic obstructive pulmonary disease. J Pharm Biomed Anal. 2014;100:369\u201380.","journal-title":"J Pharm Biomed Anal"},{"key":"2654_CR54","doi-asserted-by":"publisher","first-page":"5882","DOI":"10.1158\/0008-5472.CAN-04-0746","volume":"64","author":"Z Zhang","year":"2004","unstructured":"Zhang Z, Bast RC Jr., Yu Y, Li J, Sokoll LJ, Rai AJ, Rosenzweig JM, Cameron B, Wang YY, Meng XY, et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res. 2004;64:5882\u201390.","journal-title":"Cancer Res"},{"key":"2654_CR55","doi-asserted-by":"publisher","first-page":"e230025","DOI":"10.57264\/cer-2023-0025","volume":"12","author":"GP Reilly","year":"2023","unstructured":"Reilly GP, Gregory DA, Scotti DJ, Lederman S, Neiman WA, Sussman S, Ekono LMB. A real-world comparison of the clinical and economic utility of OVA1 and CA125 in assessing ovarian tumor malignancy risk. J Comp Eff Res. 2023;12:e230025.","journal-title":"J Comp Eff Res"},{"key":"2654_CR56","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1056\/NEJMoa2304714","volume":"390","author":"DC Chung","year":"2024","unstructured":"Chung DC, Gray DM 2nd, Singh H, Issaka RB, Raymond VM, Eagle C, Hu S, Chudova DI, Talasaz A, Greenson JK, et al. A Cell-free DNA Blood-Based Test for Colorectal Cancer Screening. N Engl J Med. 2024;390:973\u201383.","journal-title":"N Engl J Med"},{"key":"2654_CR57","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1056\/NEJMoa2310336","volume":"390","author":"TF Imperiale","year":"2024","unstructured":"Imperiale TF, Porter K, Zella J, Gagrat ZD, Olson MC, Statz S, Garces J, Lavin PT, Aguilar H, Brinberg D, et al. Next-Generation Multitarget Stool DNA Test for Colorectal Cancer Screening. N Engl J Med. 2024;390:984\u201393.","journal-title":"N Engl J Med"},{"key":"2654_CR58","first-page":"1877","volume":"22","author":"H Kumar","year":"2002","unstructured":"Kumar H, Heer K, Greenman J, Kerin MJ, Monson JR. Soluble FLT-1 is detectable in the sera of colorectal and breast cancer patients. Anticancer Res. 2002;22:1877\u201380.","journal-title":"Anticancer Res"},{"key":"2654_CR59","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/S0959-8049(96)00523-0","volume":"33","author":"H Pappot","year":"1997","unstructured":"Pappot H, Hoyer-Hansen G, Ronne E, Hansen HH, Brunner N, Dano K, Grondahl-Hansen J. Elevated plasma levels of urokinase plasminogen activator receptor in non-small cell lung cancer patients. Eur J Cancer. 1997;33:867\u201372.","journal-title":"Eur J Cancer"},{"key":"2654_CR60","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s12885-023-10523-z","volume":"23","author":"J Li","year":"2023","unstructured":"Li J, Li J, Hao H, Lu F, Wang J, Ma M, Jia B, Zhuo M, Wang J, Chi Y, et al. Secreted proteins MDK, WFDC2, and CXCL14 as candidate biomarkers for early diagnosis of lung adenocarcinoma. BMC Cancer. 2023;23:110.","journal-title":"BMC Cancer"},{"key":"2654_CR61","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/1756-9966-29-62","volume":"29","author":"GE Rice","year":"2010","unstructured":"Rice GE, Edgell TA, Autelitano DJ. Evaluation of midkine and anterior gradient 2 in a multimarker panel for the detection of ovarian cancer. J Exp Clin Cancer Res. 2010;29:62.","journal-title":"J Exp Clin Cancer Res"},{"key":"2654_CR62","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s10555-014-9547-8","volume":"34","author":"MA Elzek","year":"2015","unstructured":"Elzek MA, Rodland KD. Proteomics of ovarian cancer: functional insights and clinical applications. Cancer Metastasis Rev. 2015;34:83\u201396.","journal-title":"Cancer Metastasis Rev"},{"key":"2654_CR63","doi-asserted-by":"publisher","first-page":"188503","DOI":"10.1016\/j.bbcan.2021.188503","volume":"1875","author":"M Zhang","year":"2021","unstructured":"Zhang M, Cheng S, Jin Y, Zhao Y, Wang Y. Roles of CA125 in diagnosis, prediction, and oncogenesis of ovarian cancer. Biochim Biophys Acta Rev Cancer. 2021;1875:188503.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"2654_CR64","first-page":"59","volume":"100","author":"BC Cooper","year":"2002","unstructured":"Cooper BC, Sood AK, Davis CS, Ritchie JM, Sorosky JI, Anderson B, Buller RE. Preoperative CA 125 levels: an independent prognostic factor for epithelial ovarian cancer. Obstet Gynecol. 2002;100:59\u201364.","journal-title":"Obstet Gynecol"},{"key":"2654_CR65","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/S0009-9120(00)00182-X","volume":"33","author":"EP Diamandis","year":"2000","unstructured":"Diamandis EP, Yousef GM, Soosaipillai AR, Bunting P. Human kallikrein 6 (zyme\/protease M\/neurosin): a new serum biomarker of ovarian carcinoma. Clin Biochem. 2000;33:579\u201383.","journal-title":"Clin Biochem"},{"key":"2654_CR66","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1038\/sj.bjc.6690776","volume":"81","author":"L Hefler","year":"1999","unstructured":"Hefler L, Tempfer C, Heinze G, Mayerhofer K, Breitenecker G, Leodolter S, Reinthaller A, Kainz C. Monocyte chemoattractant protein-1 serum levels in ovarian cancer patients. Br J Cancer. 1999;81:855\u20139.","journal-title":"Br J Cancer"},{"key":"2654_CR67","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1158\/0008-5472.CAN-11-1543","volume":"72","author":"I Bertini","year":"2012","unstructured":"Bertini I, Cacciatore S, Jensen BV, Schou JV, Johansen JS, Kruhoffer M, Luchinat C, Nielsen DL, Turano P. Metabolomic NMR fingerprinting to identify and predict survival of patients with metastatic colorectal cancer. Cancer Res. 2012;72:356\u201364.","journal-title":"Cancer Res"},{"key":"2654_CR68","doi-asserted-by":"publisher","unstructured":"DiDonato S, Vignoli A, Biagioni C, Malorni L, Mori E, Tenori L, Calamai V, Parnofiello A, Di Pierro G, Migliaccio I et al. A serum metabolomics classifier derived from elderly patients with metastatic colorectal cancer predicts relapse in the adjuvant setting. Cancers (Basel). 2021;13(11):2762. https:\/\/doi.org\/10.3390\/cancers13112762.","DOI":"10.3390\/cancers13112762"},{"key":"2654_CR69","doi-asserted-by":"publisher","first-page":"537","DOI":"10.3390\/metabo11080537","volume":"11","author":"E Derveaux","year":"2021","unstructured":"Derveaux E, Thomeer M, Mesotten L, Reekmans G, Adriaensens P. Detection of Lung Cancer via Blood Plasma and (1)H-NMR Metabolomics: Validation by a Semi-Targeted and Quantitative Approach Using a Protein-Binding Competitor. Metabolites. 2021;11:537.","journal-title":"Metabolites"},{"key":"2654_CR70","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1021\/pr101050d","volume":"10","author":"E Garcia","year":"2011","unstructured":"Garcia E, Andrews C, Hua J, Kim HL, Sukumaran DK, Szyperski T, Odunsi K. Diagnosis of early stage ovarian cancer by 1H NMR metabonomics of serum explored by use of a microflow NMR probe. J Proteome Res. 2011;10:1765\u201371.","journal-title":"J Proteome Res"},{"key":"2654_CR71","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/s41586-024-07148-y","volume":"628","author":"MK Karjalainen","year":"2024","unstructured":"Karjalainen MK, Karthikeyan S, Oliver-Williams C, Sliz E, Allara E, Fung WT, Surendran P, Zhang W, Jousilahti P, Kristiansson K, et al. Genome-wide characterization of circulating metabolic biomarkers. Nature. 2024;628:130\u20138.","journal-title":"Nature"},{"key":"2654_CR72","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.3390\/cancers14071757","volume":"14","author":"U Gyllensten","year":"2022","unstructured":"Gyllensten U, Hedlund-Lindberg J, Svensson J, Manninen J, Ost T, Ramsell J, Aslin M, Ivansson E, Lomnytska M, Lycke M, et al. Next generation plasma proteomics identifies high-precision biomarker candidates for ovarian cancer. Cancers (Basel). 2022;14:1757.","journal-title":"Cancers (Basel)"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-026-02654-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02654-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02654-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:33:33Z","timestamp":1781645613000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12943-026-02654-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,7]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2654"],"URL":"https:\/\/doi.org\/10.1186\/s12943-026-02654-1","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,7]]},"assertion":[{"value":"27 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Swedish Ethical Review Authority (EPM dnr 2019 \u2212 00222) with amendments. The research was in line with informed consents obtained from patients included in U-CAN [\n                      \n                      ] (EPN Uppsala 2010 \u2212 198 with amendments) and research participants in EpiHealth [\n                      \n                      ].","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"105"}}